Search

Author/Creator Casey, M

1. 128 Bright blood t2 weighted MRI has higher diagnostic precision and accuracy than dark blood stir MRI for assessment of the ischaemic area-at-risk and myocardial salvage in acute myocardial infarction. (9th June 2011)

Authors:
Payne, A R; Casey, M; McClure, J; McGeoch, R; Murphy, A; Woodward, R; Saul, A; Gilchrist, J; Clark, C; Oldroyd, K G; Tzemos, N; Berry, C
Journal:
Heart
Issue:
Volume 97(2011)Supplement 1
Page Start:
A73
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 859TiPTALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on ≥ 1 novel hormonal therapy (NHT). (23rd October 2018)

Authors:
de Bono, J S; Higano, C; Saad, F; Miller, K; Casey, M; Czibere, A; Healy, C; Fizazi, K
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 863OAxitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results. (23rd October 2018)

Authors:
Gross-Goupil, M; Kwon, T G; Eto, M; Ye, D; Miyake, H; Seo, S I; Byun, S S; Lee, J L; Master, V; Jin, J; Debenedetto, R; Linke, R; Casey, M; Rosbrook, B; Lechuga Frean, M J; Valota, O; Grande, E; Quinn, D I
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 881PCorrelations between disease-free survival (DFS) and overall survival (OS) in patients (pts) with renal cell carcinoma (RCC) at high risk for recurrence: Results from S-TRAC trial. (23rd October 2018)

Authors:
George, D J; Pantuck, A J; Figlin, R; Escudier, B; Halabi, S; Casey, M; Lin, X; Serfass, L; Lechuga Frean, M J; Ravaud, A
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. (20th October 2018)

Authors:
Gross-Goupil, M; Kwon, T G; Eto, M; Ye, D; Miyake, H; Seo, S I; Byun, S -S; Lee, J L; Master, V; Jin, J; DeBenedetto, R; Linke, R; Casey, M; Rosbrook, B; Lechuga, M; Valota, O; Grande, E; Quinn, D I
Journal:
Annals of oncology
Issue:
Volume 29:Number 12(2018)
Page Start:
2371
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗